Erratum: Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas (Antiangiogenic Variant of TSP-1 Targets Tumor Cells in Glioblastomas (2015) 23(2) (235–243), (S152500161630034X), (10.1038/mt.2014.214));Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas

Molecular Therapy

Volumn 23, Issue 2, 2015, Pages 235-243

  Choi, Sung Hugh ^a   Tamura, Kaoru ^a   Khajuria, Rajiv Kumar ^a   Bhere, Deepak ^a   Nesterenko, Irina ^a   Lawler, Jack ^a   Shah, Khalid ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; DEATH RECEPTOR 4; DEATH RECEPTOR 5; THROMBOSPONDIN 1; THROMBOSPONDIN 1 THREE TYPE 1 REPEAT DOMAIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; CASPASE; CD36 ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MONOTHERAPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; LENTIVIRINAE; MESENCHYMAL STROMA CELL; METABOLISM; MORTALITY; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PROTEIN DOMAIN; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIGENS, CD36; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; GLIOBLASTOMA; HUMANS; LENTIVIRUS; MESENCHYMAL STROMAL CELLS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; THROMBOSPONDIN 1; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSDUCTION, GENETIC;

EID: 84922237357     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1016/j.ymthe.2024.04.022     Document Type: Erratum

References (49)

1. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG and Batchelor TT. (2007). Angiogenesis in brain tumours. Nat Rev Neurosci 8: 610-622
2. Plate KH and Mennel HD. (1995). Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 47: 89-94
3. Rampling R, Cruickshank G, Lewis AD, Fitzsimmons SA and Workman P. (1994). Direct measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 29: 427-431
4. Valk PE, Mathis CA, Prados MD, Gilbert JC and Budinger TF. (1992). Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33: 2133-2137
5. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji, Y., et al. (2010). Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 12: 233-242
6. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F., et al. (2011). Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108: 3749-3754
7. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231
8. Plate KH, Scholz A and Dumont DJ. (2012). Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited. Acta Neuropathol 124: 763-775
9. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL and Bouck N. (2000). Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6: 41-48
10. Zhang X and Lawler J. (2007). Thrombospondin-based antiangiogenic therapy. Microvasc Res 74: 90-99
11. Ren B, Song K, Parangi S, Jin T, Ye, M, Humphreys R., et al. (2009). A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. Cancer Res 69: 3856-3865
12. Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE and Zetter BR. (2005). Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by beta1 integrins. J Cell Biol 168: 643-653
13. Miao WM, Seng WL, Duquette M, Lawler P, Laus C and Lawler J. (2001). Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. Cancer Res 61: 7830-7839
14. Rich JN. (2003). The role of transforming growth factor-beta in primary brain tumors. Front Biosci 8: e245-e260
15. Sasaki A, Naganuma H, Satoh E, Nagasaka M, Isoe S, Nakano S., et al. (1995). Secretion of transforming growth factor-beta 1 and -beta 2 by malignant glioma cells. Neurol Med Chir (Tokyo) 35: 423-430
16. Platten M, Wick W and Weller M. (2001). Malignant glioma biology: role for TGF-beta in growth motility angiogenesis and immune escape. Microsc Res Tech 52: 401-410
17. Yerbes R, Palacios C and López-Rivas A. (2011). The therapeutic potential of TRAIL receptor signalling in cancer cells. Clin Transl Oncol 13: 839-847
18. Meacham CE and Morrison SJ. (2013). Tumour heterogeneity and cancer cell plasticity. Nature 501: 328-337
19. Kuijlen JM, Bremer E, Mooij JJ, den Dunnen WF and Helfrich W. (2010). Review: on TRAIL for malignant glioma therapy?. Neuropathol Appl Neurobiol 36: 168-182
20. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M., et al. (2002). Chemotherapeutic agents sensitize osteogenic sarcoma cells but not normal human bone cells to Apo2L/TRAIL-induced apoptosis. Int J Cancer 99: 491-504
21. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Büchler P, Haas TL., et al. (2006). Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 12: 2640-2646
22. Gliniak B and Le, T. (1999). Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158
23. Jacquemin G, Granci V, Gallouet AS, Lalaoui N, Morlé A, Iessi E., et al. (2012). Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells. Haematologica 97: 38-46
24. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S. (1999). Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741
25. Lacour S, Micheau O, Hammann A, Drouineaud V, Tschopp J, Solary E., et al. (2003). Chemotherapy enhances TNF-related apoptosis-inducing ligand DISC assembly in HT29 human colon cancer cells. Oncogene 22: 1807-1816
26. Ravi R, Jain AJ, Schulick RD, Pham V, Prouser TS, Allen H., et al. (2004). Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 64: 9105-9114
27. Singh TR, Shankar S, Chen X, Asim M and Srivastava RK. (2003). Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosisinducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400
28. Chen W, Hou J, Zhao Y, Qiu L, Ke, X, Wang Z, et al. (2012). Circularly permuted TRAIL (CPT) combined with thalidomide for the treatment of relapsed or refractory multiple myeloma: an open-label multicenter phase II clinical trial. 54 ASH Annual Meeting and Exposition abstr 2958
29. Micheau O, Shirley S and Dufour F. (2013). Death receptors as targets in cancer. Br J Pharmacol 169: 1723-1744
30. Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E., et al. (2011). Randomized phase II study of dulanermin in combination with paclitaxel carboplatin and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 29: 4442-4451
31. Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S, et al. (2009). Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results. J Clin Oncol 27: abstra 4129
32. Pardridge WM. (2005). The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2: 3-14
33. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W., et al. (2000). Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97: 12846-12851
34. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, Mohapatra G., et al. (2009). Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci USA 106: 4822-4827
35. Shah K, Bureau E, Kim DE, Yang K, Tang Y, Weissleder R., et al. (2005). Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression. Ann Neurol 57: 34-41
36. Stuckey DW and Shah K. (2014). Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer 14: 683-691
37. Godard S, Getz G, Delorenzi M, Farmer P, Kobayashi H, Desbaillets I., et al. (2003). Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 63: 6613-6625
38. Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK., et al. (2002). CD36, a class B scavenger receptor is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol 160: 101-112
39. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG and Kerbel RS. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239
40. Jain RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62
41. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J., et al. (2001). Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy pharmacokinetics and safety. J Pharmacol Exp Ther 299: 31-38
42. Stuckey DW and Shah K. (2013). TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 19: 685-694
43. Shah K, Tung CH, Yang K, Weissleder R and Breakefield XO. (2004). Inducible release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. Cancer Res 64: 3236-3242
44. Corsten MF and Shah K. (2008). Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol 9: 376-384
45. Schichor C, Albrecht V, Korte B, Buchner A, Riesenberg R, Mysliwietz J., et al. (2012). Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp Neurol 234: 208-219
46. Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M., et al. (2009). Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res 69: 3472-3481
47. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R and Shah K. (2007). MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 67: 8994-9000
48. Shah K, Hingtgen S, Kasmieh R, Figueiredo JL, Garcia-Garcia E, Martinez- Serrano A., et al. (2008). Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model. J Neurosci 28: 4406-4413
49. Shah K, Tang Y, Breakefield X and Weissleder R. (2003). Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 22: 6865-6872